ATIR: Interim Phase II data

Data from 10 patients with high-risk hematologic malignancies who received a single IV infusion of ATIR given

Read the full 171 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE